ZTS VS GILD Stock Comparison

Performance

ZTS
100/100

ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.

GILD
100/100

GILD returned -1.84% in the last 12 months. Based on SPY's performance of -21.15%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ZTS
75/100

21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.

GILD
63/100

28 analysts offer 12-month price targets for GILD. Together, they have an average target of 79.65, the most optimistic target put GILD at 112 within 12-months and the most pessimistic has GILD at 54.

Technicals

ZTS
82/100

ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

GILD
14/100

GILD receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

ZTS
53/100

ZTS has missed earnings 2 times in the last 20 quarters.

GILD
10/100

GILD has missed earnings 6 times in the last 20 quarters.

Profit

ZTS
78/100

Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.

GILD
67/100

Out of the last 20 quarters, GILD has had 18 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

ZTS
50/100

ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

GILD
47/100

GILD has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Dividend

ZTS
35/100

ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.

GILD
71/100

GILD's most recent dividend was $0.57 per share, based on a share price of $76.62. It was a payout ratio of 35.38% compared to their total earnings.

Sentiment

ZTS

"Sentiment" not found for ZTS

GILD
72/100

GILD had a bullish sentiment score of 71.54% across Twitter and StockTwits over the last 12 months. It had an average of 98.66 posts, 1,137.11 comments, and 3,489.66 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

ZOETIS INC. Summary

New York Stock Exchange / ZTS

Healthcare

Drug Manufacturers - Specialty & Generic

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Gilead Sciences Inc Summary

Nasdaq / GILD

Healthcare

Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Power up your portfolio